skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 2,463  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Journal Title: Cancers remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Correction: Pan et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers 2020, 12, 94
Correction: Pan et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers 2020, 12, 94
Material Type:
Article 		Add to My Research

Correction: Pan et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers 2020, 12, 94

Cancers, 2021-10, Vol.13 (21), p.5401 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13215401 ;PMID: 34771753

Full text available

Citations Cited by
2
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
Material Type:
Article 		Add to My Research

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas

Cancers, 2022-06, Vol.14 (13), p.3037 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers14133037 ;PMID: 35804808

Full text available

Citations Cited by
3
Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor In Exosome-Mediated Cytotoxicity Against Tumor
Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor In Exosome-Mediated Cytotoxicity Against Tumor
Material Type:
Article 		Add to My Research

Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor In Exosome-Mediated Cytotoxicity Against Tumor

Cancers, 2020-03, Vol.12 (3), p.661 [Peer Reviewed Journal]

2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12030661 ;PMID: 32178479

Full text available

Citations Cited by
4
A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models
A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models
Material Type:
Article 		Add to My Research

A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models

Cancers, 2023-10, Vol.15 (20), p.5080 [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15205080 ;PMID: 37894446

Full text available

Citations Cited by
5
Pancreatic Cancer Chemoresistance to Gemcitabine
Pancreatic Cancer Chemoresistance to Gemcitabine
Material Type:
Article 		Add to My Research

Pancreatic Cancer Chemoresistance to Gemcitabine

Cancers, 2017-11, Vol.9 (11), p.157 [Peer Reviewed Journal]

Copyright MDPI AG 2017 ;2017 by the authors. 2017 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers9110157 ;PMID: 29144412

Full text available

Citations Cited by
6
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Material Type:
Article 		Add to My Research

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells

Cancers, 2021-01, Vol.13 (2), p.312 [Peer Reviewed Journal]

2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13020312 ;PMID: 33467027

Full text available

Citations Cited by
7
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Material Type:
Article 		Add to My Research

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

Cancers, 2019-12, Vol.11 (12), p.2002 [Peer Reviewed Journal]

2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11122002 ;PMID: 31842362

Full text available

Citations Cited by
8
Flavonoids in Cancer and Apoptosis
Flavonoids in Cancer and Apoptosis
Material Type:
Article 		Add to My Research

Flavonoids in Cancer and Apoptosis

Cancers, 2018-12, Vol.11 (1), p.28 [Peer Reviewed Journal]

2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 by the authors. 2018 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11010028 ;PMID: 30597838

Full text available

Citations Cited by
9
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Material Type:
Article 		Add to My Research

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201

Cancers, 2022-10, Vol.14 (20), p.4999 [Peer Reviewed Journal]

COPYRIGHT 2022 MDPI AG ;2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers14204999

Full text available

Citations Cited by
10
Correction: Jannoo et al. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide. Cancers 2023, 15 , 2772
Correction: Jannoo et al. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide. Cancers 2023, 15 , 2772
Material Type:
Article 		Add to My Research

Correction: Jannoo et al. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide. Cancers 2023, 15 , 2772

Cancers, 2024-02, Vol.16 (5), p.1006 [Peer Reviewed Journal]

2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2024 by the authors. 2024 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers16051006 ;PMID: 38473435

Full text available

Citations Cited by
11
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Material Type:
Article 		Add to My Research

Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems

Cancers, 2019-05, Vol.11 (5), p.640 [Peer Reviewed Journal]

2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11050640 ;PMID: 31072061

Full text available

Citations Cited by
12
Resistance to Trastuzumab
Resistance to Trastuzumab
Material Type:
Article 		Add to My Research

Resistance to Trastuzumab

Cancers, 2022-10, Vol.14 (20), p.5115 [Peer Reviewed Journal]

COPYRIGHT 2022 MDPI AG ;2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers14205115

Full text available

Citations Cited by
13
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Material Type:
Article 		Add to My Research

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Cancers, 2020-03, Vol.12 (3), p.738 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12030738 ;PMID: 32245016

Full text available

Citations Cited by
14
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
Material Type:
Article 		Add to My Research

Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer

Cancers, 2020-07, Vol.12 (7), p.1959 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12071959 ;PMID: 32707666

Full text available

Citations Cited by
15
The Role of Macrophages in Cancer Development and Therapy
The Role of Macrophages in Cancer Development and Therapy
Material Type:
Article 		Add to My Research

The Role of Macrophages in Cancer Development and Therapy

Cancers, 2021-04, Vol.13 (8), p.1946 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13081946 ;PMID: 33919517

Full text available

Citations Cited by
16
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
Material Type:
Article 		Add to My Research

Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death

Cancers, 2020-04, Vol.12 (4), p.1047 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12041047 ;PMID: 32340275

Full text available

Citations Cited by
17
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
Material Type:
Article 		Add to My Research

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

Cancers, 2018-10, Vol.10 (10), p.387 [Peer Reviewed Journal]

2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 by the authors. 2018 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers10100387 ;PMID: 30336605

Full text available

Citations Cited by
18
IL-12 Family Cytokines in Cancer and Immunotherapy
IL-12 Family Cytokines in Cancer and Immunotherapy
Material Type:
Article 		Add to My Research

IL-12 Family Cytokines in Cancer and Immunotherapy

Cancers, 2021-01, Vol.13 (2), p.167 [Peer Reviewed Journal]

2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13020167 ;PMID: 33418929

Full text available

Citations Cited by
19
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Material Type:
Article 		Add to My Research

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

Cancers, 2020-06, Vol.12 (6), p.1473 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12061473 ;PMID: 32516895

Full text available

Citations Cited by
20
Taxol-Loaded MSC-Derived Exosomes Provide a Therapeutic Vehicle to Target Metastatic Breast Cancer and Other Carcinoma Cells
Taxol-Loaded MSC-Derived Exosomes Provide a Therapeutic Vehicle to Target Metastatic Breast Cancer and Other Carcinoma Cells
Material Type:
Article 		Add to My Research

Taxol-Loaded MSC-Derived Exosomes Provide a Therapeutic Vehicle to Target Metastatic Breast Cancer and Other Carcinoma Cells

Cancers, 2019-06, Vol.11 (6), p.798 [Peer Reviewed Journal]

2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11060798 ;PMID: 31181850

Full text available

Citations Cited by

Results 1 - 20 of 2,463  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 2014  (2)
  2. 2014 To 2017  (11)
  3. 2018 To 2019  (302)
  4. 2020 To 2022  (1,555)
  5. After 2022  (594)
  6. More options open sub menu

Subject 

  1. Cytotoxicity  (2,461)
  2. Oncology  (2,390)
  3. Life Sciences & Biomedicine  (2,383)
  4. Science & Technology  (2,383)
  5. Tumors  (1,487)
  6. Cancer Therapies  (1,329)
  7. Cancer  (1,086)
  8. Chemotherapy  (1,079)
  9. Immunotherapy  (1,027)
  10. Apoptosis  (983)
  11. Review  (966)
  12. Patients  (953)
  13. Medical Prognosis  (855)
  14. Lymphocytes  (828)
  15. Metastasis  (762)
  16. Proteins  (745)
  17. Lymphocytes T  (693)
  18. Antigens  (683)
  19. Metastases  (654)
  20. Kinases  (653)
  21. More options open sub menu

Language 

  1. Japanese  (218)
  2. Norwegian  (7)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait